Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy
Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors...
Year: 2025
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025
Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC...
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving...
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
– Results support advancement of 10 mg dose into Phase 3 development – – End-of-Phase 2 meeting request accepted by...
Halda Therapeutics Announces Oral Plenary Presentation on HLD-0915 Clinical Data in Metastatic Castration-Resistant Prostate Cancer (mCRPC) at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 24, 2025
Plenary Presentation to be Followed by Poster Presentation Highlighting HLD-0915 Clinical DataBOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics...
Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis
PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States...
Ashvattha Therapeutics Appoints Ophthalmology Veteran Robert J. Dempsey as Interim CEO Following Positive Phase 2 Results and FDA Alignment on Pivotal Program
FDA agrees with Phase 2b/3 clinical design, including primary endpoint and development approach, providing clear regulatory pathway to conduct two...
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical...
HealthEquity Introduces GLP-1 Telehealth and Direct HSA Enrollment Platforms
New Offerings Bring Millions Affordable Healthcare Solutions During Open Enrollment SeasonDRAPER, Utah, Oct. 14, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc....
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated...
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
DOYLESTOWN, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical...
Confluent Health Strengthens National Network with Addition of Commonwealth Hand & Physical Therapy
LOUISVILLE, Ky., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Confluent Health, a national leader in musculoskeletal (MSK) care, today announced its...
Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing
On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy...
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek
Late breaking session to feature results from the successful PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract...
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI®...
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
Once-daily Precision Timed Release™ (PTR™) stimulant designed to deliver rapid onset of effect and entire active-day duration NDA accepted under the...
Precision Neuroscience Named to Fast Company’s Next Big Things in Tech List
Award recognizes technology breakthroughs that promise to help define the future of their industriesNEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE)...
Milestone Scientific Highlights Operational Progress and Growth Initiatives Under New Leadership
Company outlines decisive initiatives to strengthen its dental and medical businesses, reduce operating expenses across the organization, and position Milestone...
Milestone Scientific Commits to Regaining NYSE American Compliance Following Notification
Notification has no immediate effect on the Company’s listing or day-to-day operationsROSELAND, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Milestone...
Human Appeal Statement on Gaza Ceasefire
MISSION VIEJO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Human Appeal joins the wider humanitarian community in welcoming the recently...